scholarly journals P5.106 Charting the Path For Human Papillomavirus (HPV) Vaccine Introduction in Kenya: Assessing HPV Vaccine Acceptability Among Caregivers and Opinion Leaders in Nyanza Province, Kenya

2013 ◽  
Vol 89 (Suppl 1) ◽  
pp. A368.1-A368
Author(s):  
A L Friedman ◽  
E Dunne ◽  
K Onyango ◽  
M Habel ◽  
J Ford ◽  
...  
Keyword(s):  
Human Papillomavirus ◽  
Hpv Vaccine ◽  
Opinion Leaders ◽  
Vaccine Acceptability ◽  
Nyanza Province ◽  
Vaccine Introduction ◽  
Hpv Vaccine Acceptability

Human papillomavirus vaccine acceptability among a national sample of adult women in the USA

Sexual Health ◽  
2010 ◽  
Vol 7 (3) ◽  
pp. 304 ◽  
Author(s):  
Nathan W. Stupiansky ◽  
Susan L. Rosenthal ◽  
Sarah E. Wiehe ◽  
Gregory D. Zimet
Keyword(s):  
Human Papillomavirus ◽  
Sexual Health ◽  
Health Outcomes ◽  
Hpv Vaccine ◽  
Adult Women ◽  
Vaccine Acceptability ◽  
Vaccine Cost ◽  
Health Related ◽  
The Usa ◽  
Hpv Vaccine Acceptability

Background: In the USA, the human papillomavirus (HPV) vaccine is currently licensed for 9–26-year-old females, but licensure for women over 26 years is being considered. The aim of the current study was to investigate the association of sociodemographic and health-related factors to HPV vaccine acceptability among adult women. Methods: The current study utilised a nationally representative sample of women (n = 1323) aged 27–55 living in the USA, with an oversampling of black and Latina women. A multiple item measure of HPV vaccine acceptability across varying cost and location-of-availability (clinic only v. any local pharmacy) conditions was the main outcome measure. General linear modelling was used to analyse the association of vaccine cost, location availability, and sociodemographic and health-related variables with vaccine acceptability. Results: Vaccine cost had the strongest association with acceptability [F (2, 1249) = 832.1; P < 0.0001]; however, factors such as religiosity, political views, a history of various negative sexual health outcomes and previous flu shot receipt were also associated with acceptability. Location availability had a statistically significant but modest effect, with a slight preference shown for health clinic availability. Conclusions: Adult women had generally high levels of HPV vaccine acceptability, but were greatly influenced by cost of the vaccine. Women who had experienced negative sexual health outcomes due to HPV-specific infection rated the vaccine as more acceptable, perhaps due to distress associated with those outcomes.

scholarly journals A systematic review of measures used in studies of human papillomavirus (HPV) vaccine acceptability

Vaccine ◽  
2010 ◽  
Vol 28 (24) ◽  
pp. 4027-4037 ◽  
Author(s):  
Jennifer D. Allen ◽  
Gloria D. Coronado ◽  
Rebecca S. Williams ◽  
Beth Glenn ◽  
Cam Escoffery ◽  
...  
Keyword(s):  
Systematic Review ◽  
Human Papillomavirus ◽  
Hpv Vaccine ◽  
Vaccine Acceptability ◽  
Hpv Vaccine Acceptability

Vaccinating young adults against human papillomavirus: the importance of understanding health decision-making and behaviour

Sexual Health ◽  
2007 ◽  
Vol 4 (2) ◽  
pp. 129 ◽  
Author(s):  
S. Rachel Skinner ◽  
Melissa Kang ◽  
Susan L. Rosenthal
Keyword(s):  
Human Papillomavirus ◽  
Hpv Vaccine ◽  
Hpv Vaccination ◽  
Initial Study ◽  
Quadrivalent Vaccine ◽  
Age Group ◽  
Vaccine Acceptability ◽  
Health Decision Making ◽  
Health Decision ◽  
Hpv Vaccine Acceptability

Vaccination of young teenage females against human papillomavirus (HPV) with a newly licenced quadrivalent vaccine designed to prevent cervical cancer and genital warts has recently been recommended by the Australian government and will be implemented through schools from April 2007. In addition, a fully funded ‘catch-up’ vaccination program for young women up to age 26 years has been approved for a 2-year period, from July 2007. As general practitioners (GPs) will be the main immunisation providers for this age group, in order to achieve high vaccination coverage and maximal impact on disease, it will be critical for GPs to be opportunistic in recommending this vaccine. An initial study of young Australians’ attitudes towards HPV vaccination and hypothetical acceptance of the vaccine was published in this journal. We draw on this study and data published elsewhere to discuss issues of HPV vaccine acceptability, and the likely challenges of a mass vaccination initiative in this age group in Australia. We suggest specific strategies to support GPs, and highlight areas for further research in HPV vaccine acceptability.

Human Papillomavirus (HPV) Vaccine Acceptability in Hispanic Males Living on the U.S./Mexico Border

2020 ◽  
pp. 154041532092147
Author(s):  
Gabriel Frietze ◽  
Raymond Oliva ◽  
Jessica M. Shenberger-Trujillo
Keyword(s):  
Human Papillomavirus ◽  
Hpv Vaccine ◽  
Risk Perceptions ◽  
The United States ◽  
Care Providers ◽  
Vaccine Acceptability ◽  
Hispanic Males ◽  
Mexico Border ◽  
Hpv Vaccine Acceptability ◽  
The U.S

The human papillomavirus (HPV) is the most common sexually transmitted infection in the United States, and the prevalence rate of infections is approximately 79 million. Research investigating HPV vaccine acceptability has primarily focused on female populations. The current study investigates factors associated with HPV vaccine acceptability in an underrepresented population within the literature, Hispanic males. Ninety-seven male participants ( M age = 21.68 years; SD = 3.97) were recruited from a large urban university along the U.S./Mexico border to complete a 15- to 20-minute survey. More than half of the sample reported to have had a sexual experience within the past 12 months and a fifth of these participants reported that they never use protection such as condoms. Furthermore, about half of the sample reported that they did not receive the HPV vaccine or were unaware if they received the HPV vaccine. A strong correlation emerged between individual vaccine risk perceptions and family vaccine risk perceptions ( r = .82; p < .001). The following factors emerged as predictors of vaccine acceptability: having recommendations from health care providers, having a family with positive attitudes toward vaccines, and having a family that perceives less risks associated with vaccines. Implications of the findings are discussed.

scholarly journals A qualitative study of HPV vaccine acceptability among health workers, teachers, parents, female pupils, and religious leaders in northwest Tanzania

Vaccine ◽  
2012 ◽  
Vol 30 (36) ◽  
pp. 5363-5367 ◽  
Author(s):  
Pieter Remes ◽  
Veronica Selestine ◽  
John Changalucha ◽  
David A. Ross ◽  
Daniel Wight ◽  
...  
Keyword(s):  
Qualitative Study ◽  
Hpv Vaccine ◽  
Health Workers ◽  
Religious Leaders ◽  
Vaccine Acceptability ◽  
Hpv Vaccine Acceptability

scholarly journals High Human Papillomavirus Vaccine Acceptability and Cost-Effectiveness of the Chinese 2-Valent Vaccine Among Men Who Have Sex With Men: A Cross-Sectional Study in Shenyang, China

2021 ◽  
Vol 8 ◽  
Author(s):  
Ze-Hao Ye ◽  
Zhao-Zhen Liu ◽  
Si-Tong Cui ◽  
Zhen-Xing Chu ◽  
Yong-Jun Jiang ◽  
...  
Keyword(s):  
Human Papillomavirus ◽  
Cost Effectiveness ◽  
Hpv Vaccine ◽  
Online Survey ◽  
Cost Effective ◽  
Hpv Infection ◽  
Human Papillomavirus Vaccine ◽  
Vaccine Acceptability ◽  
Cross Sectional ◽  
Sex With Men

Background: Despite the insupportable burden caused by the human papillomavirus (HPV) and high vaccine acceptability, vaccination programs are not currently available for men who have sex with men (MSM). We aimed to assess HPV infection by examining the willingness for vaccination among MSM and cost-effectiveness of the Chinese 2-valent HPV vaccine.Methods: We recruited MSM in Shenyang, China between July and December 2020 to conduct anal HPV testing and an online survey regarding HPV-related knowledge and vaccine acceptability. We performed a cost-effectiveness analysis to evaluate the incremental cost-effectiveness ratios (ICERs) of the Chinese 2-valent HPV vaccine.Results: A total of 234 participants completed the online survey; of those, 203 were successfully tested for HPV. The median age was 30 years [interquartile range (IQR): 23–38 years]. Most participants had at least undergraduate education (136/234, 58.1%). The acceptability rate for the free HPV vaccine was 57.7% (135/234). The prevalence of HPV types 16 and 18 was 14.9% (18/121) and 26.8% (22/82) in the willing and unwilling to vaccinate groups, respectively (P &gt; 0.05). The prevalence of high-risk HPV among participants aged &lt;30 and ≥50 years was 48.6 and 38.9%, respectively. Using the Chinese per capita gross domestic product (GDP) as a threshold, the Chinese 2-valent HPV vaccine would be a “very cost-effective” strategy, with an ICER value of USD 4,411. This evidence showed that the Chinese 2-valent HPV vaccine was more cost-effective than other imported vaccines.Conclusions: Targeted strategies should be utilized in MSM with different rates of vaccine acceptability. A pilot HPV vaccination program based on the Chinese 2-valent HPV vaccine for MSM is urgently warranted to reduce the burden of HPV and anal cancer.

Sign in / Sign up

Export Citation Format

Share Document